A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. States have been requested that judicious use may be made of the stock that has been already supplied as well as stock that has been allocated. The arrangements for supply will be monitored by National Pharmaceuticals Pricing Authority (NPPA). (Read More)
Be the first to comment